← Leaderboards
Christina Grek
Xequel Bio, Inc.
$5,343,622
Attributed
$5,343,622
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2015–22$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,343,622 · 5
By mechanism
R44$4,803,747 · 3
R43$539,875 · 2
Top collaborators
No co-investigators on record.
Most similar at Xequel Bio, Inc.
Same institution · by research overlap
- Gautam Sudhir Ghatnekar$7,871,466
Others in their field
Top investigators on “Formulation”
- David Heimbrook · Leidos Biomedical Research, Inc.$143,562,560
- Sharon A Nachman · Johns Hopkins University$135,132,510
- David W Simpson · University Of Southern California$88,046,235
- Jaap Goudsmit · Janessen Vaccines And Prevention, Bv$70,218,020
- Michael E Jackson · Unavco, Inc.$66,602,150
- Meghan Miller · Unavco, Inc.$66,602,150
Research focus
FormulationSmall Business Innovation Research GrantClinical ResearchConnexin 43PreventClinical TrialsBaseConnexinsCellsPeptidesToxic EffectSafetyCommunicationCell PhysiologyToxicokineticsFutureOperative Surgical ProceduresBrainDrug Delivery SystemsLinkMalignant NeoplasmsNovel TherapeuticsResistanceIn Vitro
Grant awards (9)
Improving marginal allograft outcomes through cell junction stabilization in transplantation$987,481
R44 · FY2022 · DK · contact PI
Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy$314,875
R43 · FY2022 · EY · contact PI
Improving marginal allograft outcomes through cell junction stabilization in transplantation$993,803
R44 · FY2021 · DK · contact PI
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$100,000
R44 · FY2020 · CA · contact PI
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$655,532
R44 · FY2019 · CA · contact PI
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$841,361
R44 · FY2018 · CA · contact PI
A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis$571,536
R44 · FY2018 · AR · contact PI
A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis$654,034
R44 · FY2017 · AR · contact PI
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide$225,000
R43 · FY2015 · CA · contact PI